ACTRN12620001133921招募中未知
A Randomised, Controlled, 6-week, Parallel-group, Superiority Trial to Compare the Efficacy of Sleep Hygiene, Cognitive Behavioural Therapy, Bright Light Therapy and Their Combination on Insomnia Symptoms during Chemotherapy for Breast Cancer: The Sleep, Cancer and Rest (SleepCare) Trial
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Female
入选标准
- •(a)Breast cancer diagnosis;
- •(b)Age greater than or equal to 18 years;
- •(c)Receiving oral or intravenous cytotoxic chemotherapy, with at least 6 weeks of chemotherapy treatment anticipated at the time of enrolment;
- •(d)Able to read and write in English;
- •(e)Able to provide informed consent;
- •(f)Have regular access to email and internet.
排除标准
- •(a)History of suffering migraines;
- •(b)Severe psychiatric disorder including substance use disorders;
- •(d)Daily use of sleep medications or herbal sleep aids for the previous two weeks or ongoing/planned daily use during the trial;
- •(e)Brain metastasis with daily steroid use;
- •(f)Significant symptoms of the following sleep disorders based on The Structured Clinical Interview for Sleep Disorders (SCISD-R; Taylor, Kelly, Kohut, & Song, 2017): narcolepsy, sleep apnoea, periodic limb movement disorder, restless legs syndrome, circadian rhythm sleep disorders.
研究者
相似试验
进行中（未招募）
不适用
A double-blind, randomized, 6-week, parallel-group clinicaltrial to assess the safety and efficacy of Asacol 4.8 g/day(800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mgmesalamine tablet) for the treatment of moderately activeulcerative colitis (ASCEND III) - ASCEND IIIlcerative ColitisMedDRA version: 9.1Level: LLTClassification code 10009900Term: Colitis ulcerativeEUCTR2006-001310-32-LTProcter & Gamble Technical Centres Limited770
进行中（未招募）
不适用
A double-blind, randomized, 6-week, parallel-group clinicaltrial to assess the safety and efficacy of Asacol 4.8 g/day(800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mgmesalamine tablet) for the treatment of moderately activeulcerative colitis (ASCEND III) - Ascend IIIEUCTR2006-001310-32-LVProcter & Gamble Technical Centres Limited470
进行中（未招募）
不适用
A double-blind, randomized, 6-week, parallel-group clinicaltrial to assess the safety and efficacy of Asacol 4.8 g/day(800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mgmesalamine tablet) for the treatment of moderately activeulcerative colitis (ASCEND III) - ASCEND IIIlcerative ColitisMedDRA version: 8.1Classification code 10009900EUCTR2006-001310-32-HUProcter & Gamble Technical Centres Limited770
进行中（未招募）
不适用
A double-blind, randomized, 6-week, parallel-group clinicaltrial to assess the safety and efficacy of Asacol 4.8 g/day(800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mgmesalamine tablet) for the treatment of moderately activeulcerative colitis (ASCEND III) - ASCEND IIIlcerative ColitisMedDRA version: 8.1Classification code 10009900EUCTR2006-001310-32-CZProcter & Gamble Technical Centres Limited770
进行中（未招募）
不适用
A double-blind, randomized, 6-week, parallel-group clinicaltrial to assess the safety and efficacy of Asacol 4.8 g/day(800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mgmesalamine tablet) for the treatment of moderately activeulcerative colitis (ASCEND III) - ASCEND IIIEUCTR2006-001310-32-EEProcter & Gamble Technical Centres Limited770